Albiglutide for the management of type 2 diabetes

Marc S. Rendell

Research output: Contribution to journalArticle

Abstract

Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and approved for use in type 2 diabetes. It has less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as some competitor agents. Area covered: The current use of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long-term study is now underway to determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events. At present, albiglutide is a safe agent to introduce GLP-1 RA treatment into the regimen for type 2 diabetes patients and may be the GLP-1 agent of choice in patients with renal insufficiency.

LanguageEnglish (US)
Pages1-8
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Volume13
Issue number1
DOIs
StatePublished - Jan 2 2018
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Glucagon-Like Peptide 1
Renal Insufficiency
Gastrointestinal Agents
Drug Approval
Injections
Expert Testimony
European Union
PubMed
Pancreatitis
Weight Loss
Therapeutics
Placebos
rGLP-1 protein
Food
Glucagon-Like Peptide-1 Receptor

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Albiglutide for the management of type 2 diabetes. / Rendell, Marc S.

In: Expert Review of Endocrinology and Metabolism, Vol. 13, No. 1, 02.01.2018, p. 1-8.

Research output: Contribution to journalArticle

@article{803fb5e20a97408fb7053b3682fe8056,
title = "Albiglutide for the management of type 2 diabetes",
abstract = "Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and approved for use in type 2 diabetes. It has less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as some competitor agents. Area covered: The current use of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2{\%} of participants. A large long-term study is now underway to determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events. At present, albiglutide is a safe agent to introduce GLP-1 RA treatment into the regimen for type 2 diabetes patients and may be the GLP-1 agent of choice in patients with renal insufficiency.",
author = "Rendell, {Marc S.}",
year = "2018",
month = "1",
day = "2",
doi = "10.1080/17446651.2018.1419061",
language = "English (US)",
volume = "13",
pages = "1--8",
journal = "Expert Review of Endocrinology and Metabolism",
issn = "1744-6651",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Albiglutide for the management of type 2 diabetes

AU - Rendell, Marc S.

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and approved for use in type 2 diabetes. It has less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as some competitor agents. Area covered: The current use of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long-term study is now underway to determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events. At present, albiglutide is a safe agent to introduce GLP-1 RA treatment into the regimen for type 2 diabetes patients and may be the GLP-1 agent of choice in patients with renal insufficiency.

AB - Introduction: Albiglutide is a long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection and approved for use in type 2 diabetes. It has less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as some competitor agents. Area covered: The current use of albiglutide is discussed. The review encompassed a search of PubMed and a thorough analysis of the European Union and US Food and Drug Administration approval documents. Expert opinion: Unlike competitor agents, the gastrointestinal side effects of albiglutide are not much greater than placebo. It has been studied and appears safe at all stages of renal failure. There exists concern about an imbalance of pancreatitis cases in the approval program as well as injection site reactions which led to discontinuance of therapy in up to 2% of participants. A large long-term study is now underway to determine if albiglutide, with its relatively favorable GI tolerance, has a place in the treatment of patients with increased risk of cardiovascular events. At present, albiglutide is a safe agent to introduce GLP-1 RA treatment into the regimen for type 2 diabetes patients and may be the GLP-1 agent of choice in patients with renal insufficiency.

UR - http://www.scopus.com/inward/record.url?scp=85038615766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038615766&partnerID=8YFLogxK

U2 - 10.1080/17446651.2018.1419061

DO - 10.1080/17446651.2018.1419061

M3 - Article

VL - 13

SP - 1

EP - 8

JO - Expert Review of Endocrinology and Metabolism

T2 - Expert Review of Endocrinology and Metabolism

JF - Expert Review of Endocrinology and Metabolism

SN - 1744-6651

IS - 1

ER -